title: [The comparative characteristics of the effect of immunomodulators on the indices of body nonspecific protection and on the structure of the populations of the causative agents in mixed infections].
abstract: A sharp decrease in the characteristics of nonspecific protection and humoral immunity in mixed infections (Pseudomonas aeruginosa + fungi of the genus Candida) in cases of burn traumas was established. Under these conditions an increase (up to 100%) in the number clones with the signs of pathogenicity and multiple medicinal resistance in the populations of infective agents, accompanied by a high death rate among the animals (up to 60%), was observed in the dynamics of the infectious process. The use of immunomodulators (tactivin and sodium nucleinate + lidocaine) contributed to the restoration of the phagocytic function of peripheral blood lymphocytes and humoral immunity, as well as to a decrease in the death rate of the animals. At the same time a considerable decrease in the number of clones with the signs of pathogenicity was observed in the populations in infective agents, isolated from the animals in the process of treatment.
authors.forename: E V
authors.initials: EV
authors.lastname: Shatalova
authors.forename: V V
authors.initials: VV
authors.lastname: Bel'skiĭ
authors.forename: N P
authors.initials: NP
authors.lastname: Elinov
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D002056:Burns / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology; D002176:Candida albicans / Q000187:drug effects*; D002177:Candidiasis / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D007113:Immunity, Innate / Q000187:drug effects; D008012:Lidocaine / Q000627:therapeutic use*; D051379:Mice; D008808:Mice, Inbred CBA; D009696:Nucleic Acids / Q000627:therapeutic use*; D010455:Peptides / Q000627:therapeutic use*; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D013949:Thymus Extracts / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D000276:Adjuvants, Immunologic; D009696:Nucleic Acids; D010455:Peptides; D013949:Thymus Extracts; C036191:T-activin; C013683:sodium nucleinate; D008012:Lidocaine